迈普医学
(301033)
| 流通市值：31.86亿 | | | 总市值：37.86亿 |
| 流通股本：5597.76万 | | | 总股本：6651.94万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 73,703,893.55 | 278,442,127.39 | 190,940,750.31 | 122,046,806.09 |
| 营业收入 | 73,703,893.55 | 278,442,127.39 | 190,940,750.31 | 122,046,806.09 |
| 利息收入 | 0 | - | - | - |
| 已赚保费 | 0 | - | - | - |
| 手续费及佣金收入 | 0 | - | - | - |
| 二、营业总成本 | 48,479,325.85 | 202,578,024.19 | 139,545,635.69 | 91,459,623.01 |
| 营业成本 | 14,356,380.8 | 57,563,558.12 | 41,588,231.59 | 25,807,081.93 |
| 利息支出 | 0 | - | - | - |
| 手续费及佣金支出 | 0 | - | - | - |
| 退保金 | 0 | - | - | - |
| 赔付支出净额 | 0 | - | - | - |
| 提取保险合同准备金净额 | 0 | - | - | - |
| 保单红利支出 | 0 | - | - | - |
| 分保费用 | 0 | - | - | - |
| 税金及附加 | 1,448,604.63 | 5,209,252.99 | 3,607,520.86 | 2,270,137.07 |
| 销售费用 | 11,675,610.94 | 57,205,636.83 | 33,292,798.19 | 22,769,255.41 |
| 管理费用 | 14,110,660.44 | 56,832,710.86 | 44,848,008.18 | 29,705,763.63 |
| 研发费用 | 7,846,308.01 | 27,090,650.72 | 16,632,975.62 | 11,051,898.15 |
| 财务费用 | -958,238.97 | -1,323,785.33 | -423,898.75 | -144,513.18 |
| 其中:利息费用 | 10,356.64 | 904,084.36 | 888,216.54 | 866,903.86 |
| 其中:利息收入 | 799,326.97 | 2,050,272.24 | 1,446,558.42 | 976,779.57 |
| 加:公允价值变动收益 | -594,552.73 | 151,575.36 | -57,064.1 | -65,017.46 |
| 加:投资收益 | 1,188,297.56 | 3,428,431.47 | 2,915,266.01 | 2,022,563.27 |
| 汇兑收益 | 0 | - | - | - |
| 资产处置收益 | - | 790.78 | 790.78 | - |
| 资产减值损失(新) | -29,560.99 | -69,976.92 | -837.3 | -212.18 |
| 信用减值损失(新) | -32,994.93 | -95,828.86 | -15,481.67 | -10,943.24 |
| 其他收益 | 2,779,303.07 | 12,442,950.53 | 8,777,949.07 | 6,052,381.61 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 28,535,059.68 | 91,722,045.56 | 63,015,737.41 | 38,585,955.08 |
| 加:营业外收入 | 58,383.66 | 2,613,416.1 | 10,816.77 | 10,809.64 |
| 减:营业外支出 | 277,450.96 | 1,178,367.28 | 338,820.34 | 152,927 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 28,315,992.38 | 93,157,094.38 | 62,687,733.84 | 38,443,837.72 |
| 减:所得税费用 | 4,153,685.38 | 14,302,864.15 | 9,884,757.5 | 6,053,157.93 |
| 六、净利润 | 24,162,307 | 78,854,230.23 | 52,802,976.34 | 32,390,679.79 |
| 持续经营净利润 | 24,162,307 | 78,854,230.23 | 52,802,976.34 | 32,390,679.79 |
| 归属于母公司股东的净利润 | 24,162,307 | 78,854,230.23 | 52,802,976.34 | 32,390,679.79 |
| (一)基本每股收益 | 0.37 | 1.2 | 0.8 | 0.49 |
| (二)稀释每股收益 | 0.36 | 1.2 | 0.8 | 0.49 |
| 八、其他综合收益 | 51,005.19 | 7,467.26 | 70,664.75 | 400.78 |
| 归属于母公司股东的其他综合收益 | 51,005.19 | 7,467.26 | 70,664.75 | 400.78 |
| 九、综合收益总额 | 24,213,312.19 | 78,861,697.49 | 52,873,641.09 | 32,391,080.57 |
| 归属于母公司股东的综合收益总额 | 24,213,312.19 | 78,861,697.49 | 52,873,641.09 | 32,391,080.57 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-17 |
| 审计意见(境内) | | 标准无保留意见 | | |